These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27084002)

  • 1. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
    Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT
    Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
    Lai TY; Wong RL; Chan WM
    Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M; Zoli D; Musolino M; Traverso CE
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.
    Tseng CC; Chen SN
    Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy for steroid-associated central serous chorioretinopathy.
    Lee TG; Kim JE
    Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.